Drugs / Cord Blood Units
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07566377 | Apr 2026 → Apr 2030 expected | Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, graft versus host disease +1 | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT01479582 | Oct 2011 → Nov 2012 | acute leukemia, myelodysplastic/myeloproliferative neoplasm, non-Hodgkin lymphoma, plasma cell myeloma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cord Blood Units | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07566377 ↗ |
| Known as | CBUs | “This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other...” NCT01479582 ↗ |